Artivion Q2 2026: Revenue Climbs 11%, but Acquisition Costs Deepen Net Loss; Guidance Holds Steady
AORT sits 40% above its 52-week low of $19.16.
Summary
Artivion posted Q2 2026 revenue of $125.8 million, an 11% year-over-year increase, but a GAAP net loss of $(13.5) million emerged due to acquisition costs. Non-GAAP net income reached $6.3 million, and the company reaffirmed its full-year guidance.
Key Events · Earnings and Guidance · AORT
-
Q2 Revenue Grows 11%
Total revenue reached $125.8 million, up 11% on a GAAP basis and 9% on a constant currency basis, driven by 18% growth in On-X and 12% growth in stent grafts.
-
GAAP Net Loss on Acquisition Costs
Net loss was $(13.5) million, or $(0.28) per share, compared to net income of $1.3 million in Q2 2025, primarily due to $15.5 million in business development, integration, and severance costs related to the Endospan acquisition.
-
Non-GAAP Profitability Maintained
Non-GAAP net income was $6.3 million, or $0.13 per diluted share, down from $10.7 million in Q2 2025, reflecting higher operating expenses and acquisition-related integration costs.
-
Adjusted EBITDA Up 7%
Adjusted EBITDA increased to $26.4 million from $24.8 million in Q2 2025, with margins pressured by acquisition-related spending but supported by revenue growth.
Analysis · AORT · Industrial Applications And Services
Revenue rose 11% to $125.8 million, fueled by On-X and stent grafts, yet the quarter swung to a GAAP net loss of $(13.5) million as $15.5 million in business development and integration costs from the Endospan acquisition weighed on the bottom line. Non-GAAP net income came in at $6.3 million, or $0.13 per share, while adjusted EBITDA advanced 7% to $26.4 million. Management reaffirmed the full-year 2026 outlook—revenue of $480–$496 million and adjusted EBITDA of $92–$99 million—signaling confidence despite near-term acquisition-related expenses. The results land just weeks after the transformative Endospan deal and FDA approval of AMDS, underscoring the strategic pivot toward a complete aortic arch portfolio.
At the time of this filing, AORT was trading at $26.77 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $19.16 to $48.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.